Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15257018 | 0.80 | PSIP1 (0.53) | — | |
| SCHEMBL99909 | 0.74 | — | — | |
| SCHEMBL15257019 | 0.73 | CYP3A4 (0.40) | — | |
| SCHEMBL15257023 | 0.72 | KMT2A (0.50) | KMT2A | |
| SCHEMBL15257021 | 0.72 | KMT2A (0.50) | MEN1KMT2A | |
| SCHEMBL15253892 | 0.71 | PSIP1 (0.51) | — | |
| SCHEMBL133853 | 0.70 | MEN1 (0.55) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL6122039 | 0.70 | PSIP1 (0.51) | — | |
| SCHEMBL8519235 | 0.68 | — | — | |
| SCHEMBL15257043 | 0.67 | PSIP1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150336965-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-11-26 | — | — | US | disclosed |
| US-20150336965-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-11-26 | — | — | US | disclosed |
| US-9132129-B2 | Antiviral compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-09-15 | — | — | US | disclosed |
| US-9132129-B2 | Antiviral compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-09-15 | — | — | US | disclosed |
| US-20130245049-A1 | Novel Antiviral Compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-09-19 | — | — | US | disclosed |
| US-20130245049-A1 | Novel Antiviral Compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-09-19 | — | — | US | disclosed |
| WO-2012065963-A2 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245049-A1 | Novel Antiviral Compounds | MAVS, EIF2AK2, ZC3HAV1 | MEN1 4719/4885NPC1 181/4885MAPT 2788/4885 |
| US-20150336965-A1 | NOVEL ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | MEN1 4719/4885NPC1 181/4885MAPT 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.